All the players in the game: driving home the global commitment for legitimate drugs.
Substandard, falsified, and counterfeit medications are a concern for the industry and for the public's health. Data collection and research on these illegitimate drugs must continue to be a priority and common recommendations must be implemented immediately. The health of the public continues to be at risk, and as such global consensus and collaboration must be swift. Process improvements and policy decisions can support expert recommendations while technology and research continue to drive home change. Addressing counterfeit and substandard drugs is cost effective, feasible, and the right thing to do.